Global Hematology (CBC) Analysers Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Hematology (CBC) Analysers Market Size

• The global hematology (CBC) analysers market was valued at USD 5.76 billion in 2024 and is expected to reach USD 8.01 billion by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 4.20%, primarily driven by the increased demand for accurate and rapid diagnosis
• This growth is driven by factors such as rise in chronic or infectious disease, automation and workflow efficiency and technological advancements

Hematology (CBC) Analysers Market Analysis

• Hematology (CBC) analysers are indispensable diagnostic tools used to evaluate a patient’s overall health and detect a wide range of disorders, including anemia, infection, clotting issues, and hematologic cancers. These systems provide detailed counts of red blood cells, white blood cells, platelets, hemoglobin levels, and more, playing a central role in routine medical testing
• The demand for these analysers is primarily driven by the rising global burden of chronic and infectious diseases, combined with a growing emphasis on preventive healthcare. A significant portion of this demand stems from routine diagnostic screenings and ongoing monitoring of long-term health conditions, especially in aging populations. With millions of CBC tests conducted daily worldwide, these analysers are essential for efficient, high-throughput lab operations
• Asia-Pacific has emerged as a rapidly growing market due to increasing healthcare access, investments in diagnostic infrastructure, and government-led health initiatives. However, North America remains a dominant market, benefiting from a robust diagnostic ecosystem, high test volumes, and continuous R&D investments by key players 
  • For instance, the U.S. conducts millions of CBC tests annually across hospitals, diagnostic chains, and outpatient clinics. This high demand fosters not only utilization but also technological innovation, such as integration with Laboratory Information Systems (LIS), automation, and advanced data analytics for flagging abnormalities 
• Globally, CBC analysers are regarded as one of the most critical instruments in clinical laboratories, second only to biochemistry analysers in routine usage. Their role in accurate, fast, and cost-effective diagnostics makes them a cornerstone of modern medical practice, particularly in primary care, oncology, and emergency medicine settings

Report Scope and Hematology (CBC) Analysers Market Segmentation

Hematology (CBC) Analyzers Market Trends

“Increasing Adoption of 3D Imaging and Digital Integration”

• One of the most prominent trends in the global hematology (CBC) analyzers market is the growing integration of automation, artificial intelligence (AI), and digital connectivity in laboratory systems
• These advancements are significantly transforming routine blood testing by enhancing efficiency, accuracy, and data management across clinical laboratories and diagnostic centers worldwide 
  • For instance, AI-powered algorithms are now being used to automatically classify abnormal cells, flag critical results, and reduce manual review time, which is especially beneficial in high-throughput environments such as hospital laboratories and diagnostic chains
• Furthermore, the integration of CBC analyzers with Laboratory Information Systems (LIS) enables real-time data sharing, remote monitoring, and centralized quality control, streamlining lab workflows and improving turnaround times
• This trend is reshaping the hematology diagnostics landscape by minimizing human error, supporting early disease detection, and paving the way for personalized treatment strategies, especially in oncology and hematological disorders
• As a result, there is a rising demand for next-generation hematology analyzers equipped with smart features, automation-friendly interfaces, and scalable software platforms, particularly in regions with growing healthcare digitization

Hematology (CBC) Analysers Market Dynamics

Driver

“Growing Demand Due to Rising Incidence of Blood Disorders and Chronic Diseases”

• The increasing global prevalence of blood-related disorders such as anemia, leukemia, lymphoma, and clotting disorders is a significant driver for the hematology (CBC) analyzers market. In addition, the rising burden of chronic conditions such as diabetes, cardiovascular diseases, and kidney diseases also contributes to the growing need for regular blood monitoring
• With the global population aging rapidly, older adults are more susceptible to hematologic abnormalities and require frequent CBC testing for monitoring overall health and detecting underlying issues. As a result, healthcare systems are increasingly relying on advanced hematology analyzers for routine screening and diagnostics
• CBC analyzers are also critical tools in emergency departments, ICUs, oncology centers, and outpatient labs, where rapid and accurate diagnostics are essential for clinical decision-making
• As healthcare providers strive for earlier detection, faster turnaround times, and improved diagnostic accuracy, the demand for modern hematology systems continues to grow—especially those that integrate automated processes, multi-parameter analysis, and digital connectivity

For instance:

• In March 2024, a report by the World Health Organization (WHO) stated that over 1.6 billion people globally suffer from anemia, the majority being women and children, underscoring the urgent need for accessible and reliable blood diagnostics
• According to a 2023 study published by the American Society of Hematology, the incidence of leukemia among people aged 60 and above has increased by over 20% in the past decade, further driving demand for routine hematology analysis in older populations 
• The rising prevalence of blood disorders and chronic diseases, especially among aging populations, is significantly driving global demand for advanced hematology (CBC) analyzers for accurate and efficient diagnostics

Opportunity

“Enhancing Diagnostics with AI and Machine Learning Integration”

• The integration of Artificial Intelligence (AI) and machine learning into hematology analyzers represents a major opportunity for the market. AI-powered systems can now interpret blood cell morphology, detect rare cell types, and flag critical abnormalities with greater speed and accuracy
• These systems significantly reduce manual intervention and diagnostic variability, especially in high-volume labs. They can also support predictive analytics, helping clinicians anticipate complications such as sepsis, leukemic transformations, or platelet disorders earlier than traditional methods
• Furthermore, AI-enabled CBC analyzers can seamlessly interface with electronic health records (EHRs) and laboratory information systems (LIS), supporting integrated care delivery and better clinical decision-making

For instance:

• In January 2025, a study published in Clinical Chemistry revealed that AI algorithms embedded in hematology analyzers improved diagnostic accuracy for leukemia detection by over 30%, particularly in early-stage cases.
• In October 2023, the Global Health Diagnostics Forum highlighted how AI-driven hematology platforms helped streamline workflow in over 500 hospitals worldwide, cutting average result turnaround time by nearly 50% 
• The integration of AI in hematology analyzers enhances diagnostic accuracy, streamlines lab workflows, and enables early detection of critical conditions, presenting a major opportunity for market growth

Restraint/Challenge

“High Equipment and Maintenance Costs Limiting Accessibility”

• One of the key challenges facing the hematology analyzers market is the high cost of acquisition, operation, and maintenance—especially for fully automated, multi-parameter systems
• For small and mid-sized laboratories, particularly in low-income and rural regions, the financial investment required to purchase and maintain these sophisticated analyzers can be prohibitive. This leads to ongoing reliance on older, semi-automated, or manual systems, potentially affecting diagnostic accuracy and throughput
• In addition, the need for trained personnel, regular calibration, and quality control measures further adds to the operational burden, making it harder for smaller healthcare facilities to adopt advanced technologies

For instance:

• In November 2024, a whitepaper by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reported that over 40% of small diagnostic labs in Sub-Saharan Africa are unable to upgrade to automated CBC analyzers due to cost-related constraints
• A 2023 survey conducted by the Asia-Pacific Laboratory Association indicated that maintenance and reagent costs account for up to 60% of the total lifecycle expense of high-end hematology analyzers, often discouraging smaller labs from modernization 
• High costs of acquisition, operation, and maintenance significantly hinder the adoption of advanced hematology analysers, especially in low-resource and smaller laboratory settings

Hematology (CBC) Analysers Market Scope

The market is segmented on the basis of products and services, price range and end user.

Hematology (CBC) Analysers Market Regional Analysis

“North America is the Dominant Region in the Hematology (CBC) Analysers Market”

• North America leads the global hematology (CBC) analyzers market, attributed to its well-established healthcare infrastructure, widespread adoption of advanced diagnostic technologies, and the strong presence of leading medical device manufacturers
• U.S. holds a substantial market share due to the high prevalence of chronic diseases such as cancer, cardiovascular conditions, and anemia, all of which require routine hematology testing for diagnosis and monitoring
• In addition, robust reimbursement policies, government health initiatives, and significant investments in laboratory automation and R&D support the widespread adoption of next-generation hematology systems
• The increasing demand for high-throughput, AI-enabled analyzers in hospital laboratories, reference labs, and diagnostic chains continues to fuel regional market growth

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• Asia-Pacific is poised to experience the fastest growth in the Hematology analysers market, driven by expanding healthcare infrastructure, growing awareness of preventive diagnostics, and rising incidences of blood-related and chronic diseases
• Countries such as China, India, and Japan are emerging as key markets due to their large aging populations, which are at increased risk of conditions such as anaemia, leukaemia, and other hematologic disorders requiring regular CBC testing
• Japan, with its focus on health technology innovation and a highly developed medical system, remains a critical hub for the adoption of high-end, automated hematology equipment
• Meanwhile, India and China are seeing a surge in government healthcare initiatives, public-private partnerships, and increased penetration of diagnostic services into semi-urban and rural areas. These trends, combined with the rising presence of global and regional device manufacturers, are rapidly transforming the diagnostic landscape in the region

Hematology (CBC) Analysers Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Sysmex Asia Pacific Pte Ltd (Singapore)
• Beckman Coulter, Inc. (U.S.)
• Siemens Healthcare AG (Germany)
• Bayer AG (Germany)
• HORIBA (Japan)
• Boule (Sweden)
• Bio-Rad Laboratories, Inc. (U.S.)
• NIHON KOHDEN CORPORATION (Japan)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• BioSystems (Spain)
• Diatron (Hungary)
• Drew Scientific (U.S.)
• EKF Diagnostics (U.K.)
• Ortho Clinical Diagnostics (U.S.)
• Antech Diagnostics, Inc. (U.S.)
• Perlong Medical Equipment Co., Ltd. (China)
• Shenzhen Landwind Industry Co., Ltd. (China)

Latest Developments in Global Hematology (CBC) Analysers Market

• In March 2025, Sysmex America, Inc. announced the launch of the XQ-320, the latest addition to its line of 3-part differential automated hematology analyzers, designed to deliver reliable and accurate CBC testing. Tailored for physician office laboratories, STAT labs, and other settings requiring rapid diagnostic results, the XQ-320 is the first 3-part differential analyzer to feature the innovative BeyondCare Quality Monitor
• In September 2024, Zoetis Inc., will introduce the Vetscan OptiCell, a new cartridge-based hematology analyzer powered by AI. This innovative diagnostic tool delivers advanced Complete Blood Count (CBC) analysis, enhancing efficiency and accuracy in veterinary diagnostics
• In June 2024, HORIBA, expanded its acclaimed range of compact hematology instruments by introducing new models equipped with onboard Erythrocyte Sedimentation Rate (ESR) testing. The newly launched Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) now deliver combined CBC/DIFF and ESR results from whole blood in just 60 seconds. This enhancement adds a valuable tool for inflammatory disease assessment to the instruments’ already robust capabilities 

SKU-36491